Microglia contribute to cognitive decline in hypercholesterolemic LDLr-/- mice

Matheus Scarpatto Rodrigues1, Natalia Baltazar do Nascimento1, Hemelin Resende Farias1

  • 1Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde (ICBS), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.

Journal of Neurochemistry
|September 11, 2023
PubMed

Insights

Familial hypercholesterolemia (FH) in mice is linked to microgliosis and memory deficits. Minocycline treatment improved memory by reducing microglial presence near blood vessels, not by altering phagocytic activity.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Familial hypercholesterolemia (FH) is a genetic disorder causing high LDL cholesterol.
  • FH is associated with neurological issues like memory impairment, but mechanisms are unclear.
  • Microgliosis, or brain immune cell activation, is implicated in FH-related brain changes.

Purpose of the Study:

  • To investigate the role of microgliosis in neurochemical and behavioral changes in FH.
  • To examine the effects of minocycline, a microglial inhibitor, on FH mouse models.

Main Methods:

  • Utilized LDL receptor knockout (LDLr-/-) mice as an FH model.
  • Administered minocycline or vehicle to adult LDLr-/- mice.
  • Assessed microgliosis, synaptic protein markers, blood-brain barrier integrity (claudin-5), and memory function.

Main Results:

  • LDLr-/- mice showed increased hippocampal microgliosis, altered microglial morphology, and reduced claudin-5 in the prefrontal cortex.
  • Minocycline treatment ameliorated memory impairment in LDLr-/- mice.
  • Minocycline reduced perivascular microglia in the brain but did not affect microglial phagocytic activity.

Conclusions:

  • Hippocampal microgliosis, morphological changes, and perivascular microglial presence are linked to cognitive deficits in FH.
  • Microglial phagocytic activity is not the primary driver of cognitive impairment in this FH model.
  • Targeting microglial reactivity may offer therapeutic potential for FH-related neurological complications.